ÂÜÀòÂÒÂ×

Meghann Teague has extensive work experience in the field of intellectual property and patent law. Meghann is currently working as the Head of Intellectual Property at Adaptimmune since 2023. Prior to that, they held the position of Head of IP at TCR2 Therapeutics, Inc. starting from 2022.

Their earlier experience includes working as a Patent Attorney at Cooley LLP from 2017 to 2022, and as a Patent Agent at the same company from 2012 to 2022. Before joining Cooley LLP, Meghann was the Managing Director at Getts Consulting & Project Management from 2008 to 2015.

In terms of their academic background, Meghann served as a Consultant for Product Development and Clinical Trial Management at Tolera Therapeutics from 2009 to 2012. Meghann also worked as a Postdoctoral Fellow at Northwestern University, Feinberg School of Medicine from 2008 to 2009, and at the University of Sydney from 2006 to 2008.

Meghann Teague began their education in 1997 at the University of Illinois Urbana-Champaign, where they obtained a Bachelor of Science (BS) degree in Microbiology in 2001. Following this, from 2001 to 2006, they pursued their Doctor of Philosophy (PhD) at Northwestern University, specializing in Immunology. During this time, they also attended Northwestern University - The Feinberg School of Medicine, where they focused on Immunology and Microbial Pathogenesis. Meghann furthered their education by attending Georgetown University Law Center from 2013 to 2017, earning a Juris Doctor (J.D.) degree.